Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacinação em pacientes com artrite reumatoide

Brenol, Claiton Viegas; Mota, Lícia Maria Henrique da; Cruz, Bóris Afonso; Pileggi, Gecilmara Salviato; Pereira, Ivânio Alves; Rezende, Lucila Stange; Bértolo, Manoel Barros; Freitas, Max Victor Carioca; Silva, Nílzio Antônio da; Louzada‐Júnior, Paulo; Giorgi, Rina Dalva Neubarth; Lima, Rodrigo Aires Corrêa; Pinheiro, Geraldo da Rocha Castelar

doi:10.1590/s0482-50042013000100002

Cited by 7 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,43,44 Systematic vaccination of patients with RA is recommended by the BSR and rea rmed in international guidelines such as the EULAR. 12,45 Although immunosuppressed patients were excluded from phase 3 clinical trials of the e cacy and safety of immunizers against SARS-CoV-2, their vaccination was considered a priority due to the increased risk of hospitalization and death from COVID-19. In this study, both immunizers had a good safety pro le.…”

Section: Resultsmentioning

confidence: 99%

“…Non-live vaccines are safe during immunosuppression, despite the potential impairment of immunogenicity, with a similar safety pro le to the general population. 12 RA patients are at increased risk of hospitalization and death from COVID-19 due to comorbidities and immunosuppressive treatment. In addition, they have reduced immunogenicity compared with general population, especially when treated with rituximab, abatacept, methotrexate, and glucocorticoids.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study Safer

Cruz,

Guimarães,

Rêgo

et al. 2023

Preprint

View full text Add to dashboard Cite

BACKGROUND Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. Patients with rheumatoid arthritis (RA) are at a high risk of severe COVID-19 outcomes, especially those under immunosuppression or with comorbidities associated. However, few studies in the literature assessed the safety of the COVID-19 vaccine in patients with RA. OBJECTIVE Evaluate the safety of vaccines against SARS-CoV-2 in patients with RA. METHODS These data are from the study “Safety and Efficacy on COVID-19 Vaccine in Rheumatic Diseases,” a Brazilian multicentric prospective phase IV study to evaluate COVID-19 vaccine in IMRDs in Brazil. Adverse events (AEs) in patients with RA of all centers were assessed after two doses of ChAdOx1 (Oxford/AstraZeneca) or CoronaVac (Sinovac/Butantan). Stratification of postvaccination AEs was performed using a diary, filled out daily and returned at the end of 28 days for each dose. RESULTS A total of 188 patients with RA were include in the study, most of them female. CoronaVac was used in 109 patients and ChAdOx1 in 79. Only mild AEs were observed, mainly after the first dose. The more common AEs after the first dose were pain at the injection (46,7%), headache (39,4%), arthralgia (39,4%), myalgia (30,5%) and fatigue (26,6%), and ChAdOx1 had a higher frequency of pain at the injection (66% vs 32%, p < 0.001) arthralgia (62% vs 22%, p < 0.001) and myalgia (45% vs 20%, p < 0.001) compared to CoronaVac. The more common AEs after the second dose were pain at the injection (37%), arthralgia (31%), myalgia (23%), headache (21%) and fatigue (18%). Arthralgia (41,42% vs 25%, p = 0.02) and pain at injection (51,43% vs 27%, p = 0.001) were more common with ChAdOx1. Only nonsevere AEs were related, and no patients had flare after the vaccination. CONCLUSION In the comparison between the two immunizers in patients with RA, the local reactions and musculoskeletal symptoms were more frequent with ChAdOx1 than in CoronaVac, especially in the first dose. In general, the AE occurred mainly after the first dose, and were mild, like previous data from others immunizing agents in patients with rheumatoid arthritis. Vaccination did not worsen the degree of disease activity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study Safer

Cruz,

Guimarães,

Rêgo

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Due to greater susceptibility to infections, it is suggested that updating the vaccination record of patients who have indications for IB therapy be implemented, aiming to reduce the risk of some infections and, consequently, reduce the morbidity and mortality rate in this specific group of patients. 91 Preferably, the vaccination card should be updated two to four weeks before starting potentially immunosuppressive therapies, including IBs. 92 , 93 Vaccination of contacts is also an important guideline.…”

Section: Vaccination: How To Proceed In Patients Undergoing Immunobio...mentioning

confidence: 99%

“…Whenever possible, the vaccination schedule must be completed, taking into account the intervals between the withdrawal of the drugs being used and immunization. 91 , 92 , 93 , 94…”

Section: Vaccination: How To Proceed In Patients Undergoing Immunobio...mentioning

confidence: 99%

Infections in the era of immunobiologicals

Romiti,

Hirayama,

Porro

et al. 2024

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

“…Several countries, such as United Kingdom, France, Germany, United States, Mexico, and Argentina, have established vaccination calendars for these individuals 1 , 2 , 4 , 7 , 8 , 13 .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Reference Centers for Special Immunobiologicals implementation

2016

View full text Add to dashboard Cite

OBJECTIVE To describe the Reference Centers for Special Immunobiologicals and evaluate their implementation considering formal regulations.METHODS We conducted a program evaluation, of evaluative research type. From August 2011 to January 2012, a questionnaire was applied to the 42 Reference Centers for Special Immunobiologicals existing in the Country, approaching the structure, human resources, and developed activities dimensions. We conducted a descriptive analysis of data and used a clustering for binary data with the squared Euclidean distance, by the farthest neighbor method, to aggregate services with similar features.RESULTS We observed great diversity among the services in the three dimensions. The clustering resulted in five service profiles, named according to their characteristics. 1) Best structure: 12 Reference Centers for Special Immunobiologicals with the highest proportion of services with the minimum of rooms recommended, purpose-built vaccine refrigerators, preventive maintenance of the cold chain, and oxygen source. 2) Immunobiologicals distributor: six Reference Centers for Special Immunobiologicals that distributed more than applied immunogens; no doctor present for more than half of the working hours and no purpose-built vaccine refrigerators . 3) Incipient implementation: five Reference Centers for Special Immunobiologicals with inadequate structure, such as absence of purpose-built vaccine refrigerators, preventive maintenance of the cold chain and oxygen source; none had computer. 4) Vaccination rooms: 13 Reference Centers for Special Immunobiologicals, everyone did routine immunization, most participated in vaccination campaigns. 5) Teaching and research: six services, all inserted into teaching hospitals, developed researches and received trainees; most had doctors in more than half of the working hours.CONCLUSIONS The evaluation of the Reference Centers for Special Immunobiologicals implementation was based on the profiles found and considered the official regulations: services categorized as “better structure” and “teaching and research” were considered implemented; “immunobiologicals distributor” and “vaccination room” services, partially implemented, and the ones with the “incipient implementation” profile, not implemented. The results of this evaluation can contribute to the reformulation of the services, considering the current context.

show abstract

Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacinação em pacientes com artrite reumatoide

Cited by 7 publications

References 52 publications

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study Safer

Safety of Coronavac and ChAdOx1 Vaccines Against SARS-CoV-2 in Patients with Rheumatoid Arthritis Data from the Brazilian Multicentric Study Safer

Infections in the era of immunobiologicals

Evaluation of Reference Centers for Special Immunobiologicals implementation

Contact Info

Product

Resources

About